Incorporated in 2001, Sai Parenteral Ltd. is a diversified pharmaceutical formulations company with expertise in research, development, and manufacturing. The company operates in two primary segments: Branded Generic Formulations and Contract Development and Manufacturing Organisation (CDMO) products and services, catering to both domestic and international markets.

Product Portfolio and Therapeutic Areas
Sai Parenteral’s product portfolio spans multiple therapeutic areas, including cardiovascular, neuropsychiatry, anti-diabetic, respiratory health, antibiotics, gastroenterology, vitamins, minerals and supplements (VMS), analgesics, and dermatology. Its offerings cover various dosage forms such as injectables, tablets, capsules, liquid orals, and ointments, allowing the company to serve a broad spectrum of patient needs.

Manufacturing and Operations
The company operates five manufacturing facilities in India. Four are located in Hyderabad, Telangana, including GMP-compliant injectable units, a WHO-GMP injectable unit, a TGA-Australia and PIC/S accredited solid oral dosage unit, and a WHO-GMP cephalosporin facility. Its wholly owned subsidiary, Revat Laboratories, operates a GMP-certified facility in Ongole, Andhra Pradesh. Sai Parenteral entered the export market in FY 2023 after acquiring internationally accredited facilities in Hyderabad and now supplies regulated and semi-regulated markets in Australia, New Zealand, Southeast Asia, the Middle East, and Africa. As of December 31, 2025, the company employed 298 full-time employees.

Key Strengths
Sai Parenteral is a well-diversified generic formulations company with an established track record. Its strategically located and accredited manufacturing facilities support a strong focus on the CDMO business, while its well-established domestic and international distribution network enhances market reach. The company has a history of value-accretive acquisitions and benefits from experienced promoters and senior management with extensive domain knowledge.